Reuters logo
BRIEF-VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214
October 4, 2017 / 11:18 AM / in 2 months

BRIEF-VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214

Oct 4 (Reuters) - Viking Therapeutics Inc:

* VIKING THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF VK0214 IN IN VIVO MODEL OF X-LINKED ADRENOLEUKODYSTROPHY (X-ALD)

* VIKING THERAPEUTICS INC - VK0214-TREATED ANIMALS DEMONSTRATED STATISTICALLY SIGNIFICANT REDUCTIONS IN VLCFA LEVELS WITHIN KEY TISSUES​

* VIKING - ‍VK0214 LED TO STATISTICALLY SIGNIFICANT REDUCTIONS IN PLASMA LEVELS OF MULTIPLE VLCFAS IN TREATED ANIMALS COMPARED WITH VEHICLE CONTROLS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below